Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 novel antimicrobial combination therapy for tuberculous meningitis
PACTR202503871271189Phase 2Not yet recruiting
- Sponsor
- David Boulware
- Start
- Dec 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bedaquiline, pretomanid, linezolid, moxifloxacin, pyrazinamide and 3 more in meningeal tuberculosis (2 arms), sponsored by David Boulware. Primary endpoint: Hierarchical composite primary endpoint. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
bedaquilinepretomanidlinezolidmoxifloxacinpyrazinamide
03
Conditions
meningeal tuberculosis
Beyond the preview
Go deeper on PACTR202503871271189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202503871271189.